Margaret J Zhou1, Michelle Y Doral1, Steven G DuBois1, Judith G Villablanca2, Gregory A Yanik3, Katherine K Matthay4. 1. Department of Pediatrics, University of California San Francisco School of Medicine and UCSF Benioff Children's Hospital, San Francisco, CA, United States. 2. Department of Pediatrics, Keck School of Medicine University of Southern California and Children's Hospital Los Angeles, Los Angeles, CA, United States. 3. Department of Pediatrics, University of Michigan Health System, Ann Arbor, MI, United States. 4. Department of Pediatrics, University of California San Francisco School of Medicine and UCSF Benioff Children's Hospital, San Francisco, CA, United States. Electronic address: matthayk@peds.ucsf.edu.
Abstract
BACKGROUND: (131)I-metaiodobenzylguanidine ((131)I-MIBG) is a targeted radiopharmaceutical with significant activity in high-risk relapsed and chemotherapy-refractory neuroblastoma. Our primary aim was to determine if there are differences in response rates to (131)I-MIBG between patients with relapsed and treatment-refractory neuroblastoma. METHODS: This was a retrospective cohort analysis of 218 patients with refractory or relapsed neuroblastoma treated with (131)I-MIBG at UCSF between 1996 and 2014. Results were obtained by chart review and database abstraction. Baseline characteristics and response rates between relapsed patients and refractory patients were compared using Fisher exact and Wilcoxon rank sum tests, and differences in overall survival (OS) were compared using the log-rank test. RESULTS: The response rate (complete and partial response) to (131)I-MIBG-based therapies for all patients was 27%. There was no difference in response rates between relapsed and refractory patients. However, after (131)I-MIBG, 24% of relapsed patients had progressive disease compared to only 9% of refractory patients, and 39% of relapsed patients had stable disease compared to 59% of refractory patients (p=0.02). Among all patients, the 24-month OS was 47.0% (95% confidence interval (CI) 39.9-53.9%). The 24-month OS for refractory patients was significantly higher at 65.3% (95% CI 51.8-75.9%), compared to 38.7% (95% CI 30.4-46.8%) for relapsed patients (p<0.001). CONCLUSIONS: Although there was no significant difference in overall response rates to (131)I-MIBG between patients with relapsed versusrefractory neuroblastoma, patients with prior relapse had higher rates of progressive disease and had lower 2-year overall survival after (131)I-MIBG compared to patients with refractory disease.
BACKGROUND: (131)I-metaiodobenzylguanidine ((131)I-MIBG) is a targeted radiopharmaceutical with significant activity in high-risk relapsed and chemotherapy-refractory neuroblastoma. Our primary aim was to determine if there are differences in response rates to (131)I-MIBG between patients with relapsed and treatment-refractory neuroblastoma. METHODS: This was a retrospective cohort analysis of 218 patients with refractory or relapsed neuroblastoma treated with (131)I-MIBG at UCSF between 1996 and 2014. Results were obtained by chart review and database abstraction. Baseline characteristics and response rates between relapsed patients and refractory patients were compared using Fisher exact and Wilcoxon rank sum tests, and differences in overall survival (OS) were compared using the log-rank test. RESULTS: The response rate (complete and partial response) to (131)I-MIBG-based therapies for all patients was 27%. There was no difference in response rates between relapsed and refractory patients. However, after (131)I-MIBG, 24% of relapsed patients had progressive disease compared to only 9% of refractory patients, and 39% of relapsed patients had stable disease compared to 59% of refractory patients (p=0.02). Among all patients, the 24-month OS was 47.0% (95% confidence interval (CI) 39.9-53.9%). The 24-month OS for refractory patients was significantly higher at 65.3% (95% CI 51.8-75.9%), compared to 38.7% (95% CI 30.4-46.8%) for relapsed patients (p<0.001). CONCLUSIONS: Although there was no significant difference in overall response rates to (131)I-MIBG between patients with relapsed versusrefractory neuroblastoma, patients with prior relapse had higher rates of progressive disease and had lower 2-year overall survival after (131)I-MIBG compared to patients with refractory disease.
Authors: Kelsey Johnson; Barbara McGlynn; Jennifer Saggio; Diane Baniewicz; Hongming Zhuang; John M Maris; Yael P Mosse Journal: Pediatr Blood Cancer Date: 2011-04-14 Impact factor: 3.167
Authors: Steven G DuBois; Louis Chesler; Susan Groshen; Randall Hawkins; Fariba Goodarzian; Hiroyuki Shimada; Greg Yanik; Michael Tagen; Clinton Stewart; Yael P Mosse; John M Maris; Denice Tsao-Wei; Araz Marachelian; Judith G Villablanca; Katherine K Matthay Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531
Authors: Wendy B London; Victoria Castel; Tom Monclair; Peter F Ambros; Andrew D J Pearson; Susan L Cohn; Frank Berthold; Akira Nakagawara; Ruth L Ladenstein; Tomoko Iehara; Katherine K Matthay Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2014-01-31 Impact factor: 508.702
Authors: Alexei L Polishchuk; Steven G Dubois; Daphne Haas-Kogan; Randall Hawkins; Katherine K Matthay Journal: Cancer Date: 2011-03-08 Impact factor: 6.860
Authors: Katherine K Matthay; Brian Weiss; Judith G Villablanca; John M Maris; Gregory A Yanik; Steven G Dubois; James Stubbs; Susan Groshen; Denice Tsao-Wei; Randall Hawkins; Hollie Jackson; Fariba Goodarzian; Heike Daldrup-Link; Ashok Panigrahy; Alexander Towbin; Hiroyuki Shimada; John Barrett; Norman Lafrance; John Babich Journal: J Nucl Med Date: 2012-06-14 Impact factor: 10.057
Authors: K K Matthay; B Shulkin; R Ladenstein; J Michon; F Giammarile; V Lewington; A D J Pearson; S L Cohn Journal: Br J Cancer Date: 2010-04-27 Impact factor: 7.640
Authors: Austin P Dove; Bogdan-Alexandru Manole; Daniel V Wakefield; Shane J Cross; Michael Doubrovin; Barry L Shulkin; Thomas E Merchant; Andrew M Davidoff; Wayne L Furman; Matthew J Krasin; Victor M Santana; John T Lucas Journal: Pediatr Blood Cancer Date: 2018-09-30 Impact factor: 3.167
Authors: Megan Trieu; Steven G DuBois; Elizabeth Pon; Lorenzo Nardo; Randall A Hawkins; Araz Marachelian; Clare J Twist; Julie R Park; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2015-10-27 Impact factor: 3.167
Authors: Brian D Weiss; Gregory Yanik; Arlene Naranjo; Fan F Zhang; Wendy Fitzgerald; Barry L Shulkin; Marguerite T Parisi; Heidi Russell; Stephan Grupp; Luke Pater; Peter Mattei; Yael Mosse; Hollie A Lai; Jason A Jarzembowski; Hiroyuki Shimada; Judith G Villablanca; Roger Giller; Rochelle Bagatell; Julie R Park; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2021-05-24 Impact factor: 3.838